Northwest Biotherapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 22
- Market Cap
- -
- Website
- http://www.nwbio.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer
- Conditions
- Brain MetastasesLung Cancer MetastaticBreast Cancer Metastatic
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- Northwest Biotherapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT03638765
- Locations
- 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
- Conditions
- GBMGlioblastoma Multiforme
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- Northwest Biotherapeutics
- Registration Number
- NCT02146066
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸UCLA Medical Center, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital, Newport Beach, California, United States
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
- Conditions
- Colorectal CancerPancreatic CancerLocally Advanced TumorMetastatic Solid Tissue TumorsLiver CancerMelanoma
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Northwest Biotherapeutics
- Target Recruit Count
- 60
- Registration Number
- NCT01882946
- Locations
- 🇺🇸
Orlando Health, Orlando, Florida, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
- Conditions
- Grade IV AstrocytomaBrain CancerGlioblastomaGliomaBrain TumorGlioblastoma MultiformeGBM
- Interventions
- Drug: Dendritic cell immunotherapy
- First Posted Date
- 2002-09-19
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Northwest Biotherapeutics
- Target Recruit Count
- 348
- Registration Number
- NCT00045968
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Sutter East Bay Neuroscience Institute-Eden Medical Center, Castro Valley, California, United States
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.
- Conditions
- Prostate Cancer
- First Posted Date
- 2002-08-08
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Northwest Biotherapeutics
- Registration Number
- NCT00043212
- Locations
- 🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸University of California, San Diego Medical Center, San Diego, California, United States
News
Northwest Biotherapeutics to Present Next-Generation Dendritic Cell Therapy Advances at Cancer Immunotherapy Conference
Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will present on "supercharged" dendritic cells with enhanced anti-tumor effects at the Frontiers in Cancer Immunotherapy Conference on June 16.